KR960006920A - 혈액 항응고제에 대한 해독제로서 사용하기에 적합한 약제 및 이의 용도 - Google Patents

혈액 항응고제에 대한 해독제로서 사용하기에 적합한 약제 및 이의 용도 Download PDF

Info

Publication number
KR960006920A
KR960006920A KR1019950026511A KR19950026511A KR960006920A KR 960006920 A KR960006920 A KR 960006920A KR 1019950026511 A KR1019950026511 A KR 1019950026511A KR 19950026511 A KR19950026511 A KR 19950026511A KR 960006920 A KR960006920 A KR 960006920A
Authority
KR
South Korea
Prior art keywords
prothrombin
blood anticoagulants
antidote
agent according
pharmaceuticals suitable
Prior art date
Application number
KR1019950026511A
Other languages
English (en)
Inventor
뢰미슈 위르겐
디흘 칼-하인쯔
슈퇴르 한스-아르놀트
Original Assignee
슈타인. 뵈즐
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈타인. 뵈즐, 베링베르케 아크티엔게젤샤프트 filed Critical 슈타인. 뵈즐
Publication of KR960006920A publication Critical patent/KR960006920A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

혈액 항응고제에 대한 해독제로서 사용되며 프로트롬빈을 함유하는 약제가 기술되어 있다.

Description

혈액 항응고제에 대한 해독제로서 사용되며 사용하기에 적합한 약제 및 이의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 혈액 항응고제를 길항시키기 위gks 프로트롬빈을 함유하는 약제.
  2. 제1항에 있어서, 프로트롬빈이, 통상적으로 또는 유전자 조작에 의해 제조되는 프로트롬빈의 활성 단편 또는 변이체를 의미하는 약제.
  3. 제1항에 있어서, 치료할 환자의 체중 1kg당 1 내지 2000국제 단위(IU) 농도의 프로트롬빈을 함유하는 약제.
  4. 제3항에 있어서, 프로트롬빈 농도가 치료할 환자의 체중 1kg당 10 내지 1000IU인 약제.
  5. 혈액 항응고체를 길항시키기 위한 제1항의 약제를 제조하기 위한 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950026511A 1994-08-26 1995-08-25 혈액 항응고제에 대한 해독제로서 사용하기에 적합한 약제 및 이의 용도 KR960006920A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4430204.5 1994-08-26
DE4430204A DE4430204A1 (de) 1994-08-26 1994-08-26 Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung

Publications (1)

Publication Number Publication Date
KR960006920A true KR960006920A (ko) 1996-03-22

Family

ID=6526563

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950026511A KR960006920A (ko) 1994-08-26 1995-08-25 혈액 항응고제에 대한 해독제로서 사용하기에 적합한 약제 및 이의 용도

Country Status (8)

Country Link
EP (1) EP0700682A3 (ko)
JP (1) JP3838680B2 (ko)
KR (1) KR960006920A (ko)
AU (1) AU708409B2 (ko)
CA (1) CA2156990A1 (ko)
DE (1) DE4430204A1 (ko)
IL (1) IL115057A0 (ko)
ZA (1) ZA957140B (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030031380A (ko) * 2001-10-13 2003-04-21 이우진 스케이트 보드
KR20040046045A (ko) * 2002-11-26 2004-06-05 김재영 동소재를 이용한 바둑판과 장기판 및 그 제조 방법

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19625642A1 (de) * 1996-06-26 1998-01-08 Max Planck Gesellschaft Verfahren zur Herstellung einer Antidotausgangssubstanz für natürliche und synthetische Thrombininhibitoren
WO2003099324A1 (fr) * 2002-05-23 2003-12-04 Chugai Seiyaku Kabushiki Kaisha Agent neutralisant l'inhibiteur du facteur tissulaire et agent neutralisant la preparation du facteur viii active de coagulation sanguine
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
EP1874928A1 (en) 2005-04-13 2008-01-09 AstraZeneca AB A host cell comprising a vector for production of proteins requiring gamma-carboxylation
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
AU2011313505B2 (en) 2010-10-06 2015-09-17 Medimmune Limited Factor II and fibrinogen for treatment of haemostatic disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5850202B2 (ja) * 1977-11-10 1983-11-09 第一製薬株式会社 プロトロンピンの製法
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
DD251078A1 (de) * 1986-07-17 1987-11-04 Bezirksinstitut Fuer Blutspend Verfahren zur herstellung von prothrombinkonzentraten
GB8729822D0 (en) * 1987-12-22 1988-02-03 Central Blood Lab Authority Chemical process
EP0333356A3 (en) 1988-03-04 1990-12-19 Biogen, Inc. Hirudin peptides
JPH0219400A (ja) * 1988-07-07 1990-01-23 Green Cross Corp:The トロンビンまたはプロトロンビンの製造方法
US5240913A (en) 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
ATE103982T1 (de) * 1990-01-26 1994-04-15 Immuno Ag Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
DE4203965A1 (de) * 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
AT397391B (de) * 1992-05-15 1994-03-25 Immuno Ag Verwendung von prothrombinfragmenten

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030031380A (ko) * 2001-10-13 2003-04-21 이우진 스케이트 보드
KR20040046045A (ko) * 2002-11-26 2004-06-05 김재영 동소재를 이용한 바둑판과 장기판 및 그 제조 방법

Also Published As

Publication number Publication date
ZA957140B (en) 1996-03-26
JPH0859505A (ja) 1996-03-05
EP0700682A3 (de) 1996-05-29
JP3838680B2 (ja) 2006-10-25
EP0700682A2 (de) 1996-03-13
IL115057A0 (en) 1995-12-08
CA2156990A1 (en) 1996-02-27
DE4430204A1 (de) 1996-02-29
AU708409B2 (en) 1999-08-05
AU3025695A (en) 1996-03-07

Similar Documents

Publication Publication Date Title
MY138860A (en) Hiv protease inhibitors.
DE3171620D1 (en) A dried, sterilized, gamma-globulin-fixed column and a process for preparing the same
PT88930A (pt) Processo para a preparacao de novos analogos de nucleosidos e de composicoes farmaceuticas que os contem
NL970045I2 (nl) Desulfatohirudinen, werkwijze voor hun bereiding en farmaceutische middelen.
DK0853660T3 (da) Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
HUT59005A (en) Process for producing transdermal pharmaceutical preparations containing 2-amino-6-(propyl-amino)-4,5,6,7-tetrahydro-benzothiazole
KR890011606A (ko) 항응고제
NO890259L (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
BR9405763A (pt) Processo para tratar fluido corpóreo processo para tratar produto de sangue e processo para fornecer produtos de sangue a paciente
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
KR880007079A (ko) 레트로비루스에 감염된 환자치료에 있어서의 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 사용법
KR960006920A (ko) 혈액 항응고제에 대한 해독제로서 사용하기에 적합한 약제 및 이의 용도
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
KR910021361A (ko) 항궤양 물질
ES546974A0 (es) Un procedimiento de eliminacion del virus lav.
KR890003373A (ko) 수면장애 및 우울증 치료에 화합물의 이용
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
DE3764559D1 (de) 4-benzyloxy-3-pyrrolin-2-on-1-yl-acetamid, dessen herstellung und verwendung.
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
KR900017587A (ko) 바이러스 감염증 치료제의 제조를 위한 티아졸 유도체 티프로티모드의 용도
KR880012226A (ko) 외 용 제
WO1988007367A3 (en) Melatonin-derivatives for psychogenic stress and acute anxiety, and immuno-stimulant drugs
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
PT96828A (pt) Processo para a preparacao de um agente para a terapia de gangrena diabetica,contendo o factor xiii de coagulacao do sangue

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid